Roots Analysis has done a detailed study on “Digital Health Market: Focus on Digital Therapeutics (2nd Edition), 2020-2030 (Based on Type of Solution (Software Solution, Gaming Solution and Combination Solution), Type of Therapy (Curative and Preventive), and Purpose of Solution (Medication Replacement and Medication Augmentation” covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

To order this 500+ page report, which features 160+ figures and 200+ tables, please visit this link

Key Market Insights
 Eminent representatives from companies across the world attest to the fact that there is growing interest in the digital therapeutics market, highlighting the prevalent and anticipated trends in R&D and adoption
 Over 100 industry players are engaged in evaluating the potential of several prescription (validated through clinical research) digital therapeutic solutions to prevent / treat various chronic diseases
 The pipeline features a variety of digital health applications and therapy solutions that are in different stages of development, being investigated for diverse purposes, across a wide-range of clinical conditions
 These solutions have demonstrated applicability across more than 20 therapeutic areas; several products have been marketed / approved for the treatment or prevention of mental health problems and metabolic disorders
 In pursuit of a competitive edge, digital therapeutic solution developers are focusing on the integration of advanced features into their respective products and affiliated offerings
 In the last few years, over 220 clinical trials evaluating the potential benefits of digital therapeutics in close to 80,000 patients, have been registered; most of these were / are being conducted at various centers in the US
 Apart from the clinical benefit, cost is another key determinant of the acceptance and adoption of such novel interventions; pricing strategy matrix is likely to assist players to evaluate competitive market prices for solutions
 To support the ongoing innovation in this field, several private and public investors have made substantial capital investments, amounting to approximately USD 1.7 billion, in various initiatives of stakeholders
 The growing interest in this field is reflected by the increase in partnership activity, involving both international and indigenous stakeholders, across different geographical marketplaces
 In order to promote the adoption of proprietary digital health solutions, developers are actively exploring various marketing strategies in order to highlight key features of their products across a number of platforms
 Several digital monitoring / diagnostic solutions are also available to manage / diagnose patients for various chronic diseases; specifically, these remote monitoring solutions have gained interest during COVID-19
 Given the rising incidence of chronic clinical conditions and a growing pipeline of modern medicines to treat such diseases, the market for evidence-based digital therapeutics is poised to grow at a CAGR of ~20% till 2030
 The projected market opportunity is anticipated to be well-distributed across different therapeutic areas, distribution channels and key geographical regions

For more information, please visit https://www.rootsanalysis.com/reports/view_document/digital-health-market-focus-on-digital-therapeutic-monitoring-and-diag/208.html

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1 Chapter Overview
3.2. Digitization in the Healthcare Sector
3.3. Next-Generation Healthcare Solutions

3.4. Key Concepts Associated with Digital Health Solutions
3.4.1. Cognitive Behavioral Therapy (CBT)
3.4.2. Internet of Things (IoT)
3.4.3. Big Data
3.4.4. Artificial Intelligence (AI)
3.4.5. Gamification

3.5. Overview of Digital Therapeutics
3.5.1. Key Strategic Initiatives
3.5.1.1. Digital Therapeutics Alliance (DTA)
3.5.1.2. Personal Connected Health (PCH) Alliance
3.5.1.3. Programs Initiated by The Centers for Disease Control and Prevention (CDC)
3.5.1.4. Health Insurance Portability and Accountability Act (HIPAA)
3.5.1.5. National Health Service (NHS) Guidelines
3.5.1.6. United States Food and Drug Administration (USFDA) Regulations for Digital Therapeutics

3.5.2. Product Development and Commercialization Path for Digital Therapeutics
3.5.2.1. Discovery and Preclinical Phase
3.5.2.2. Clinical Trials and Validation
3.5.2.3. Involving Insurance Providers / Payers
3.5.2.4. Distribution and Marketing

4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Digital Therapeutics: Overall Market Landscape
4.2.1. Analysis by Status of Development
4.2.2. Analysis by Type of Solution
4.2.3. Analysis by Type of Therapy
4.2.4. Analysis by Purpose of Solution
4.2.5. Analysis by Target Disease Indication(s)
4.2.6. Analysis by Therapeutic Area
4.2.7. Analysis by Target Population

4.3. Digital Therapeutics: Additional Information
4.3.1. Analysis by Prescription Requirement
4.3.2. Analysis by Duration of Course
4.3.3. Analysis by Cost of Solution

4.4. Digital Therapeutics: List of Developers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Type of Business Model
4.4.4. Analysis by Location of Headquarters

4.5. Leading Developers: Analysis by Number of Digital Therapeutics Solutions
4.6. Leading Developers: 4D Bubble Analysis based on Portfolio Strength, Target Indication and Company Size
4.7. Grid Representation: Analysis by Status of Development, Type of Solution and Therapeutic Area
4.8. Tree Map Representation: Analysis by Therapeutic Area and Company Size
4.9. World Map Representation: Analysis of Regional Activity
4.10. Digital Therapeutics: Information on Additional Companies

5. PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Assumptions / Key Parameters
5.4. Key Therapeutic Areas
5.4.1. Cardiovascular Disorders
5.4.1.1. Product Competitiveness Analysis

5.4.2. Mental Health Problems
5.4.2.1. Product Competitiveness Analysis

5.4.3. Metabolic Disorders
5.4.3.1. Product Competitiveness Analysis

5.4.4. Neurological Disorders
5.4.4.1. Product Competitiveness Analysis

5.4.5. Substance Use Disorders
5.4.5.1. Product Competitiveness Analysis

5.4.6. Other Therapeutic Areas
5.4.6.1. Product Competitiveness Analysis

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Akili Interactive
6.2.1 Company Overview
6.2.2. Product Portfolio
6.2.3. Recent Developments and Future Outlook

6.3. Big Health
6.3.1. Company Overview
6.3.2. Product Portfolio
6.3.3. Recent Developments and Future Outlook

6.4. dreem
6.4.1. Company Overview
6.4.2. Product Portfolio
6.4.3. Recent Developments and Future Outlook

6.5 Kaia Health
6.5.1. Company Overview
6.5.2. Product Portfolio
6.5.3. Recent Developments and Future Outlook

6.6. Mindmaze
6.6.1. Company Overview
6.6.2. Product Portfolio
6.6.3. Recent Developments and Future Outlook

6.7. Omada Health
6.7.1. Company Overview
6.7.2. Product Portfolio
6.7.3. Recent Developments and Future Outlook

6.8. Pear Therapeutics
6.8.1. Company Overview
6.8.2. Product Portfolio
6.8.3 Recent Developments and Future Outlook

6.9. Vida Health
6.9.1. Company Overview
6.9.2. Product Portfolio
6.9.3. Recent Developments and Future Outlook

6.10. Voluntis
6.10.1. Company Overview
6.10.2. Product Portfolio
6.10.3. Recent Developments and Future Outlook

6.11. WellDoc
6.11.1. Company Overview
6.11.2. Product Portfolio
6.11.3. Recent Developments and Future Outlook

6.12. Wellthy Therapeutics
6.12.1. Company Overview
6.12.2. Product Portfolio
6.12.3. Recent Developments and Future Outlook

7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology

7.3. Digital Therapeutics: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Phase
7.3.3. Analysis by Number of Patients Enrolled and Trial Registration Year
7.3.4. Analysis by Study Design
7.3.5. Analysis by Trial Recruitment Status
7.3.6. Analysis by Sponsor / Collaborator
7.3.7. Leading Industry Players: Analysis by Number of Registered Trials
7.3.8 Leading Digital Therapeutic Solutions: Analysis by Number of Registered Trials
7.3.9. Analysis by Trial Focus
7.3.10. Analysis by Therapeutic Area
7.3.11. Geographical Analysis by Number of Clinical Trials
7.3.12. Geographical Analysis by Trial Recruitment Status
7.3.13. Geographical Analysis by Enrolled Patient Population

7.4. Clinical End-Points Analysis

8. FUNDING AND INVESTMENT ANALYSIS
8.1. Chapter Overview
8.2. Types of Funding

8.3. Digital Therapeutics: Funding and Investment Analysis
8.3.1. Analysis by Number of Funding Instances
8.3.2. Analysis by Amount Invested
8.3.3. Analysis by Type of Funding
8.3.4. Analysis by Type of Therapy
8.3.5. Analysis by Therapeutic Area
8.3.6. Analysis by Geography
8.3.7. Most Active Players: Analysis by Number of Funding Instances
8.3.8. Most Active Players: Analysis by Amount of Funding
8.3.9. Most Active Investors: Analysis by Number of Instances

8.4 Concluding Remarks

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Digital Therapeutics: Recent Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership

9.3.2. Analysis by Type of Partnership
9.3.2.1. Analysis by Type of Partnership and Year of Partnership
9.3.2.2. Analysis by Type of Partnership and Company Size

9.3.3. Analysis by Type of Partner
9.3.3.1. Analysis by Type of Partner and Year of Partnership
9.3.3.2. Analysis by Type of Partner and Type of Partnership

9.3.4. Analysis by Type of Therapy
9.3.4.1. Analysis by Type of Therapy and Type of Partnership
9.3.4.2. Analysis by Type of Therapy and Type of Partner

9.3.5. Analysis by Therapeutic Area
9.3.5.1. Analysis by Therapeutic Area and Year of Partnership
9.3.5.2 Analysis by Therapeutic Area and Type of Partner

9.3.6. Most Active Players: Analysis by Number of Partnerships
9.3.7. Regional Analysis
9.3.8. Intercontinental and Intracontinental Agreements

10. GO-TO-MARKET STRATEGY
10.1. Chapter Overview
10.2. Marketing Strategies Adopted by Digital Therapeutic Developers
10.2.1. Participation in Global Events
10.2.2. Marketing on Social Media Platforms
10.2.3. Marketing on Online / Print Media Platforms
10.2.4. Undertaking Various Promotional Activities through Official Websites
10.2.5. Adoption of Different Business Models and Pricing Strategies
10.2.5.1. B2C Business Model
10.2.5.2. B2B Business Model
10.2.5.2. B2B2C Business Model

10.2.6. Undertaking Various Promotional Activities through Product Add-ons
10.3. Concluding Remarks

11. BOWMAN CLOCK PRICING STRATEGY ANALYSIS
11.1. Chapter Overview
11.2. Bowman Strategy Clock
11.2.1. Two Dimensions of Bowman Strategy Clock
11.2.2. Eight Positions on Bowman Strategic Clock

11.3 Roots Analysis Framework
11.3.1. Methodology
11.3.2. Theoretical Framework and Price Evaluation Hypothesis
11.3.3. Results and Interpretation
11.3.3.1. Product Price Evaluation Matrix: Based on Status of Development
11.3.3.2. Product Price Evaluation Matrix: Based on Type of Solution
11.3.3.3. Product Price Evaluation Matrix: Based on Purpose of Solution
11.3.3.4. Product Price Evaluation Matrix: Based on Type of Therapy
11.3.3.5. Product Price Evaluation Matrix: Based on Therapeutic Area
11.3.3.6. Product Price Evaluation Matrix: Based on Prescription Requirement
11.3.3.7. Product Price Evaluation Matrix: Based on Course Duration
11.3.3.8. Product Price Evaluation Matrix: Based on Distribution Channel
11.4. Concluding Remarks

12. MARKET FORECAST
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Global Digital Therapeutics Market, 2020-2030

12.4. Global Digital Therapeutics Market: Distribution by Type of Solution
12.4.1. Digital Therapeutics Market for Standalone Software Applications, 2020-2030
12.4.2. Digital Therapeutics Market for Combination Offerings (Software Application + Device + Personal Coach), 2020-2030
12.4.3. Digital Therapeutics Market for Combination Offerings (Software Application + Device + AI Support), 2020-2030
12.4.4. Digital Therapeutics Market for Combination Offerings (Software Application + Device), 2020-2030
12.4.5. Digital Therapeutics Market for Combination Offerings (Software Application + AI Support), 2020-2030
12.4.6. Digital Therapeutics Market for Combination Offerings (Software Application + Personal Coach), 2020-2030
12.4.7. Digital Therapeutics Market for Other Types of Solutions, 2020-2030

12.5. Global Digital Therapeutics Market: Distribution by Purpose of Solution
12.5.1. Digital Therapeutics Market for Medication Replacement Solutions, 2020-2030
12.5.2. Digital Therapeutics Market for Medication Augmentation Solutions, 2020-2030

12.6. Global Digital Therapeutics Market: Distribution by Type of Therapy
12.6.1 Digital Therapeutics Market for Curative Therapy, 2020-2030
12.6.2. Digital Therapeutics Market for Preventive Therapy, 2020-2030

12.7. Global Digital Therapeutics Market: Distribution by Business Model
12.7.1. Digital Therapeutics Market for B2C Model (Patients and Caregivers), 2020-2030
12.7.2. Digital Therapeutics Market for B2B Model (Healthcare Providers, Payers, Employers and Pharmaceutical Companies), 2020-2030

12.8. Global Digital Therapeutics Market: Distribution by Therapeutic Area
12.8.1. Digital Therapeutics Market for Cardiovascular Disorders, 2020-2030
12.8.2. Digital Therapeutics Market for Chronic Pain, 2020-2030
12.8.3. Digital Therapeutics Market for Mental Health Problems, 2020-2030
12.8.4. Digital Therapeutics Market for Metabolic Disorders, 2020-2030
12.8.5. Digital Therapeutics Market for Neurological Disorders, 2020-2030
12.8.6. Digital Therapeutics Market for Respiratory Disorders, 2020-2030
12.8.7. Digital Therapeutics Market for Sleep Disorders, 2020-2030
12.8.8. Digital Therapeutics Market for Substance Use Disorders, 2020-2030
12.8.9. Digital Therapeutics Market for Other Disorders, 2020-2030

12.9. Global Digital Therapeutics Market: Distribution by Geography
12.9.1 Digital Therapeutics Market in North America, 2020-2030
12.9.1.1 Digital Therapeutics Market in the US, 2020-2030
12.9.1.2 Digital Therapeutics Market in Canada, 2020-2030

12.9.2 Digital Therapeutics Market in Europe, 2020-2030
12.9.2.1. Digital Therapeutics Market in France, 2020-2030
12.9.2.2. Digital Therapeutics Market in Germany, 2020-2030
12.9.2.3. Digital Therapeutics Market in Italy, 2020-2030
12.9.2.4. Digital Therapeutics Market in Spain, 2020-2030
12.9.2.5. Digital Therapeutics Market in the UK, 2020-2030
12.9.2.6. Digital Therapeutics Market in Rest of Europe, 2020-2030

12.9.3. Digital Therapeutics Market in Asia-Pacific, 2020-2030
12.9.3.1. Digital Therapeutics Market in Australia, 2020-2030
12.9.3.2. Digital Therapeutics Market in China, 2020-2030
12.9.3.3. Digital Therapeutics Market in India, 2020-2030
12.9.3.4. Digital Therapeutics Market in Japan, 2020-2030
12.9.3.5. Digital Therapeutics Market in South Korea, 2020-2030
12.9.3.6. Digital Therapeutics Market in Rest of Asia-Pacific, 2020-2030

12.9.4. Digital Therapeutics Market in Rest of the World, 2020-2030

13. CASE STUDY: IMPACT OF CORONAVIRUS OUTBREAK
13.1. Chapter Overview
13.2. Impact of Coronavirus Pandemic on Digital Therapeutics
13.2.1. Impact on Future Market Opportunity for Digital Therapeutic Solutions Market

13.3. Recuperative Strategies for Developer Businesses
13.3.1. Strategies for Implementation in the Short / Mid Term
13.3.2. Strategies for Implementation in the Long Term

14. REMOTE DIGITAL MONITORING / DIAGNOSTIC SOLUTIONS
14.1. Chapter Overview
14.2. An Introduction to Remote Digital Monitoring / Diagnostic Solutions
14.3. Remote Digital Monitoring / Diagnostic Solutions: Overall Market Landscape
14.3.1. Analysis by Status of Development
14.3.2. Analysis by Type of Solution
14.3.3. Analysis by Target Disease Indication(s)
14.3.4. Analysis by Therapeutic Area
14.3.5. Grid Representation: Analysis by Status of Development, Type of Solution, and Therapeutic Area

14.4. Remote Digital Monitoring / Diagnostic Solutions: List of Developers
14.4.1. Analysis by Year of Establishment
14.4.2. Analysis by Company Size
14.4.3. Analysis by Location of Headquarters

14.5. Remote Digital Monitoring / Diagnostic Solutions: Company Profiles
14.5.1. AliveCor
14.5.1.1. Company Snapshot
14.5.1.2. Product Portfolio
14.5.1.3. Recent Developments and Future Outlook

14.5.2. Bioserenity
14.5.2.1. Company Snapshot
14.5.2.2. Product Portfolio
14.5.2.3. Recent Developments and Future Outlook

14.5.3. Cue
14.5.3.1. Company Snapshot
14.5.2.2. Product Portfolio
14.5.2.3. Recent Developments and Future Outlook

14.5.4. Kinsa
14.5.4.1. Company Snapshot
14.5.4.2. Product Portfolio
14.5.4.3. Recent Developments and Future Outlook

14.6. Remote Digital Monitoring / Diagnostic Solutions: Funding and Investment Analysis
14.6.1. Types of Funding
14.6.2. Remote Digital Monitoring / Diagnostic Solutions: List of Funding and Investments
14.6.2.1. Analysis by Number of Funding Instances
14.6.2.2. Analysis by Amount Invested
14.6.2.3. Analysis by Type of Funding
14.6.2.4. Most Active Players: Analysis by Number of Funding Instances
14.6.2.5. Most Active Players: Analysis by Amount Invested
14.6.2.6. Most Active Investors: Analysis by Number of Funding Instances

14.7. Concluding Remarks

15. SWOT ANALYSIS
15.1. Chapter Overview
15.2. Comparison of SWOT Factors
15.2.1. Strengths
15.2.2. Weaknesses
15.2.3. Opportunities
15.2.4. Threats

16. DIGITAL SOLUTIONS: RECENT TRENDS AND FUTURE OPPORTUNITIES
16.1. Chapter Overview
16.2. Prevalent Trends Related to Digital Therapeutics
16.2.1. Emerging Focus Areas
16.2.2. Key Historical Trends
16.2.3. Geographical Distribution of Activity

16.3. Trends Shaping the Future of Digital Therapeutics
16.3.1. Digital Solutions Closing the Digital Gap
16.3.2. Increasing Focus on Patient Centric Models
16.3.3. Applicability across a Variety of Disease Indications
16.3.4. Increasing Emphasis on Real-World Evidence in Research and Development
16.3.5. Advances in IT and Computing Power to Foster Future Innovation
16.4. Improving the Future Health: Opportunities Beyond Digital Therapeutics

17. EXECUTIVE INSIGHTS
17.1. Chapter Overview
17.2. Vida Health
17.2.1. Company Snapshot
17.2.2. Interview Transcript: Stephanie Tilenius, Co-Founder and Chief Executive Officer

17.3. Canary Health
17.3.1. Company Snapshot
17.3.2. Interview Transcript: Adam Kaufman, Chief Executive Officer

17.4. Floreo
17.4.1. Company Snapshot
17.4.2. Interview Transcript: Vijay Ravidran, Chief Executive Officer

17.5. Somatix
17.5.1. Company Snapshot
17.5.2. Interview Transcript: Eran Ofir, Chief Executive Officer

17.6. Tilak Healthcare
17.6.1. Company Snapshot
17.6.2. Interview Transcript: Edouard Gasser, Chief Executive Officer

17.7. Wellthy Therapeutics
17.7.1. Company Snapshot
17.7.2. Interview Transcript: Palakh R Saraogi, Vice President Marketing, Arani Sarkra, Senior Manager Consumer Marketing, and Yolande D’Mello, Marketing and Public Relations

17.8. Voluntis
17.8.1. Company Snapshot
17.8.2. Interview Transcript: Amelie Janson, Communications Manager

17.9. Anonymous
17.9.1. Interview Transcript: Anonymous, Founder and Chief Executive Officer

18. APPENDIX 1: TABULATED DATA

19. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]